Medtronic MiniMed IPO Priced at $20
Analysis based on 10 articles · First reported Feb 24, 2026 · Last updated Mar 06, 2026
The IPO of Medtronic===Medtronic MiniMed is expected to generate significant interest in the medical device and healthcare sectors, potentially leading to increased investment in diabetes management technologies. For Medtronic, this spin-off allows it to unlock value from its diabetes unit while maintaining a substantial ownership stake, which could positively impact its stock performance.
Medtronic===Medtronic MiniMed, a subsidiary of Medtronic, has priced its initial public offering (IPO) of 28 million shares at $20.00 per share, aiming to raise $560 million. The shares are set to begin trading on the Nasdaq Global Select Market on March 6, 2026, under the ticker symbol 'MMED'. Medtronic will retain approximately 90.03% ownership of Medtronic===Medtronic MiniMed post-IPO. The proceeds from the offering will be used for general corporate purposes, to repay intercompany debt owed to Medtronic, and as additional consideration for assets transferred during the separation. Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are leading the offering as active bookrunners, supported by several other financial institutions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard